Home›Research›Compare›Liraglutide vs Tirzepatide
Peptide ComparisonLiraglutide vs Tirzepatide
Both are Metabolic peptides.
Liraglutide
Victoza
Half-life: 13 hours
53 providers listed
Tirzepatide
Dual GLP-1
Half-life: ~5 days (once-weekly dosing)
577 providers listed
Tirzepatide has a longer half-life than Liraglutide, so it generally needs less frequent dosing.
Liraglutide
Half-life
13 hours
Tirzepatide
Half-life
~5 days (once-weekly dosing)
| Your goal | Better option |
|---|---|
| Less frequent dosing (longer half-life) | Tirzepatide |
| More provider options (53 vs 577) | Tirzepatide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Liraglutide
Tirzepatide
Liraglutide
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
+4 more
Tirzepatide
Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2)
Tirzepatide Once Weekly for the Treatment of Obesity
Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
Real-World Effectiveness of Tirzepatide in Japanese Patients with Type 2 Diabetes: A Multicenter Retrospectiv…
+5 more
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
About Tirzepatide
Tirzepatide is a dual agonist of both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors. GIP receptor activation adds a complementary mechanism to GLP-1 agonism — enhancing insulin secretion, reducing glucagon, and modulating adipose tissue metabolism independently of GLP-1 pathways. The combination produces greater average weight reduction in clinical trials than selective GLP-1 agonists at comparable doses.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Liraglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Tirzepatide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
FDA prescribing protocols track HbA1c and fasting glucose for glycemic response, calcitonin for thyroid C-cell risk (black box warning), and lipase for pancreatitis screening. Baseline renal and hepatic panels are standard.
Liraglutide
Not enough vendor pricing yet.
Tirzepatide
Where to source these peptides
Liraglutide
53 listed
Browse directory →
Providers offeringTirzepatide
577 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated October 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Liraglutide vs Tirzepatide — Per-mg Price Comparison. Retrieved October 26, 2026, from https://peptidebase.io/peptides/compare/liraglutide/tirzepatide